近年来,随着人类基因组计划的进展及对功能基因的不断探索,基因治疗的研究受到越来越多人的关注,由于其展现出良好的应用前景,纳米生物医学技术在多数发达国家已经被列入优先科研计划[1]。在基因治疗的过程中,如何将所需的功能基因更为有效、安全的导入受体细胞尤为重要。目前常用的基因转染载体有病毒型和非病毒型两种。病毒型载体的转运能力较强,但其携带基因的大小及数量有限、靶向特异性差,且可诱发机体产生免疫反应[2],甚至存在较为严重的生物安全隐患[3],因此应用受到了较多的限制;非病毒型载体虽然无免疫原性,较为安全,但是其在体内存在不稳定性、转染效率低的缺点尤为突出。由此可见,目前安全、低毒、靶向及转染效率等问题 In recent years, with the progress of the human genome project and the continuous exploration of functional genes, more and more attention has been paid to the study of gene therapy. Because of its good application prospects, nanobiomedicine technology has been used in most developed countries Included in the priority research plan [1]. In the process of gene therapy, how to import the functional genes required more efficiently and safely into recipient cells is particularly important. Commonly used gene transfer vectors are viral and non-viral two. Viral vectors have strong transport capacity, but their gene size and number are limited, their targeting specificity is poor, and the immune response can be induced in the body [2], and even more serious biosafety hazards [3] More non-viral vector non-immunogenic, safer, but its instability in the body, the disadvantage of low transfection efficiency is particularly prominent. Thus, the current security, low toxicity, targeting and transfection efficiency and other issues